DAHTA database

The DAHTA database contains the HTA-reports of DIMDI as well as other institutions in the German Health Care System, like the Institute for Quality and Efficiency in Health Care (IQWiG), or the Austrian Ludwig Boltzmann Institute (LBI).

Moreover, current international HTA reports are continuously included in the database together with the German translation of the detailed summaries. This information is supplemented by comments and substantial information which appeared after publication of a report.

The link to the full text is available for every document.


Evaluation of medical procedures, medicine, health economics, social and ethical aspects


HTA-reports, methodical information, comments


German, English, French, Spanish


1998 to present


704 (Status 07/2018)




Searching the DAHTA database is free of charge.


Please use the help with the search.


Medical Subject Headings-MeSH (CT) thesaurus with polyhierarchical structure)
Language of vocabulary: MeSH Medical Subject Headings, German MeSH.

The hierarchical structure of the thesaurus allows a one step search for indented descriptors. MeSH descriptors can be limited as far as the subject is concerned e. g. therapy for a disease. Please use the expert search entering for example for dementia the following command:
CTG=Demenz/QF=th for German vocabulary
CT=Dementia/QF=th for English vocabulary
You will find further qualifier are in the appendix.

Should a MeSH-descriptor be the major topic of a document, it is weighted and marked in the document by an asterisk (MYOCARDIAL INFARCTION/*). You can search for weighted descriptors with the command CT=.../W=1.

Searchable Fields:

The following document sections are considered:

  • Abstract (AB)
  • Controlled Terms (CT)
  • Controlled Terms German (CTG)
  • Document Type (DT)
  • Notes (NOTE)
  • Publishing Data (PU)
  • Series Title (SE)
  • Title (TI)
  • Uncontrolled Terms (UT)
  • Uncontrolled Terms German (UTG)

Search language(s):
English, German.


Field Name Notes
AB Abstract Many Abstracts bilingual (in German and English).
AU Author Masking with ? is recommended, if the first names are unknown. Umlauts are searched.
CT Controlled Terms English MeSH-Terms are available for each document.
QF Qualifier There are German equivalences for each qualifier.
CTG Controlled Terms German German MeSH-Terms are available for each document.
QFG Qualifier There are German equivalences for each qualifier.
W Weight Weighting of Controlled Terms.
DOI Digital Object Identifier A DOI is a unique and persistent identification code for digital objects.
Must be set in quotation marks.
DT Document Type  
EDR Editor  
EDT Edition Statement  
FRD First Release Date Search for documents that entered the database for the first time in 2015 (This datafield was first implemented in 8/2015)
ISSN ISSN International Standard Serial Number.
LA Language Gives the language of the main document. If there is an abstract in another language, the information is here.
ND Number of Document Each document has a number which corresponds to the order of its inclusion in the database.
NOTE Notes Only existing in a few documents.
NR Number of Report Comprises the institution of origin and its continuous publications in the DAHTA.
OTI Original Title Title in original language. Is part of TI.
PU Publishing Data Name of the publishing institution.
PY Publication Year  
SE Series Title Name of series.
SO Source Contains VOL, EDT, PY and URLSO.
TI Title Contains OTI (Original Title) and TTI (Translated Title).
TRANS Translations  
TTI Translated Title Is part of TI.
URLSO URL in Source Links to the full text and further pdf files.
URN Uniform Resource Name  
UT Uncontrolled Terms  
UTG Uncontrolled Terms German  
VOL Volume  



2/1 von 14        DIMDI: DAHTA-Datenbank (DAHTA) © Deutsches Institut für Medizinische Dokumentation und Information

NR:  IQWiG228
AU:  Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen; IQWiG
TI Kosten-Nutzen-Bewertung von Venlafaxin, Duloxetin, Bupropion und Mirtazapin im Vergleich zu weiteren verordnungsfähigen medikamentösen Behandlungen
Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments
EDR:  Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen; IQWiG
SO: (1. Auflage) /2015/
  http://portal.dimdi.de/de/hta/hta_berichte/hta588_summary_de.pdf (305 KB)
  http://portal.dimdi.de/de/hta/hta_berichte/hta588_summary_en.pdf (343 KB)
LA:  Deutsch
Summary auf Englisch
DT Evidenzbasierter Bericht
AB:  HINTERGRUND: Der Gemeinsame Bundesausschuss (G-BA) hat mit Schreiben vom 17.12.2009 unter Bezugnahme auf § 35b SGB V in Verbindung mit § 10a Abs. 1 und Abs. 2, 4. Kapitel der Verfahrensordnung des G-BA das Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) mit der Kosten-Nutzen-Bewertung (KNB) von Venlafaxin, Duloxetin, Bupropion und Mirtazapin im Vergleich zu weiteren verordnungsfähigen medikamentösen Behandlungen beauftragt. Aufgrund der mit der Einführung des Arzneimittelmarktneuordnungsgesetzes (AMNOG) geänderten rechtlichen Vorgaben für das Institut wurden die Ergebnisse des Vorberichts auf Basis der Literaturrecherchen des Jahres 2010 (Nutzendaten und gesundheitsökonomische Evaluationen) bzw. 2011 (Kostendaten) nicht aktualisiert. Den Ergebnissen wird eine Übersicht zu einem möglichen Aktualisierungsbedarf gegenübergestellt. FRAGESTELLUNG: Ziel der vorliegenden Untersuchung ist, auf Basis der Ergebnisse einer Nutzenbewertung der Prüfsubstanzen Venlafaxin, Duloxetin, Bupropion und Mirtazapin eine Kosten-Nutzen-Bewertung für diese Prüfsubstanzen durchzuführen, um daraus eine Empfehlung für einen Erstattungsbetrag abzuleiten. In die Kosten-Nutzen-Bewertung werden die relevanten Komparatoren des Indikationsgebiets (trizyklische Antidepressiva plus Maprotilin, selektive Serotonin-Wiederaufnahmehemmer, Agomelatin, Trazodon) einbezogen. Die Untersuchungspopulation besteht aus nicht vorbehandelten erwachsenen Patienten mit Depression... (siehe hta588_summary_de.pdf).
BACKGROUND: In its letter of 17 December 2009, referring to § 35b SGB V in connection with § 10a (1, 2), Chapter 4 of the Code of Procedure of the Federal Joint Committee (G-BA), the G-BA commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) with the health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments. Due to a change in legal requirements for the Institute with the introduction of the Act on the Reform of the Market for Medicinal Products (AMNOG), the results of the preliminary report, which were based on the literature searches of the year 2010 (benefit data and health economic evaluations) and 2011 (cost data), were not updated. The results are contrasted with an overview of a potential need for updating. RESEARCH QUESTION: On the basis of the results of a benefit assessment of the test drugs venlafaxine, duloxetine, bupropion, and mirtazapine, the aim of the present investigation is to conduct a health economic evaluation of these test drugs in order to derive a recommendation for a reimbursement price. The relevant comparators of the therapeutic area (tricyclic antidepressants [TCAs] plus maprotiline, selective serotonin reuptake inhibitors [SSRIs], agomelatine, and trazodone) were included in the health economic evaluation. The study population consisted of previously untreated adult patients with depression... (see hta588_summary_en.pdf).
FRD:  20150805



Information on copyrights of DIMDI you will find on our German database information DAHTA.


Deutsches Institut für Medizinische Dokumentation und Information (DIMDI)

Waisenhausgasse 36-38a
50676 Köln
Phone: +49 221 4724-1
Fax: +49 221 4724-444


Public Relations
Phone: +49 221 4724-531
E-mail: Press Office


Technical Helpdesk
Phone: +49 221 4724-270
E-mail: Technical Helpdesk


1. Alphabetical List of Qualifiers

abbreviation qualifier
 AB abnormalities
 AD administration & dosage
 AE adverse effects
 AG agonists
 AA analogs & derivatives
 AN analysis
 AH anatomy & histology
 AI antagonists & inhibit.
 BI biosynthesis
 BL blood
 BS blood supply
 CF cerebrospinal fluid
 CS chemical synthesis
 CI chemically induced
 CH chemistry
 CL classification
 CO complications
 CN congenital
 CT contraindications
 CY cytology
 DF deficiency
 DI diagnosis
 DH diet therapy
 DE drug effects
 DT drug therapy
 EC economics
 ED education
 EM embryology
 EN enzymology
 EP epidemiology
 ES ethics
 EH ethnology
 ET etiology
 GE genetics
 GD growth & development
 HI history
 IM immunology
 IN injuries
 IR innervation
 IS instrumentation
 IP isolation & purific
 LJ legisl.& jurispr.
 MA manpower
 ME metabolism
 MT methods
 MI microbiology
 MO mortality
 NU nursing
 OG organizat.& administ.
 PS parasitology
 PY pathogenicity
 PA pathology
 PK pharmacokinetics
 PD pharmacology
 PH physiology
 PP physiopathology
 PO poisoning
 PC prevention & control
 PX psychology
 RE radiation effects
 RA radiography
 RI radionuclide imaging
 RT radiotherapy
 RH rehabilitation
 SC secondary
 SE secretion
 ST standards
 SN statistics & numer.data
 SD supply & distribution
 SU surgery
 TU therapeutic use
 TH therapy
 TO toxicity
 TM transmission
 TR transplantation
 TD trends
 US ultrasonography
 UL ultrastructure
 UR urine
 UT utilization
 VE veterinary
 VI virology


2. Groups of Qualifiers

"Subheading Trees"

AN: analysis
  BL: blood
  CF: cerebrospinal fluid
  IP: isolation & purification
  UR: urine
AH: anatomy & histology
  BS: blood supply
  CY: cytology
    PA: pathology
    UL: ultrastructure
  EM: embryology
    AB: abnormalities
  IR: innervation
CH: chemistry
  AG: agonists
  AA: analogs & derivates
  AI: antagonists & inhibitors
  CS: chemical synthesis
DI: diagnosis
  PA: pathology
  RA: radiography
  RI: radionuclide imaging
  US: ultrasonography
ET: etiology
  CI: chemically induced
  CO: complications
    SC: secondary
  CN: congenital
  EM: embryology
  GE: genetics
  IM: immunology
  MI: microbiology
    VI: virology
  PS: parasitology
  TM: transmission
OG: organization & administration
  EC: economics
  LJ: legislation & jurisprudence
  MA: manpower
  ST: standards
  SD: supply & distribution
  TD: trends
  UT: utilization
PD: pharmacology
  AD: admin. & dosage
  AE:  adverse effects
    PO: poisoning
    TO: toxicity
  AG: agonists
  CT: contraindications
  PK: pharmacokinetics
PH: physiology
  GE: genetics
  GD: growth & development
  IM: immunology
  ME: metabolism
    BI: biosynthesis
    BL: blood
    CF: cerebrospinal fluid
    DF: deficiency
    EN: enzymology
    PK: pharmacokinetics
    UR: urine
  PP: physiopathology
  SE: secretion
SN: Statistik & numer. data
  EP: epidemiology
    EH: ethnology
    MO: mortality
TU: therapeutic use
  AD: administration & dosage
  AE: adverse effects
  CT: contraindications
  PO: poisoning
TH: therapy
  DH: diet therapy
  DT: drug therapy
  NU: nursing
  PC: prevention & control
  RT: radiotherapy
  RH: rehabilitation
  SU: surgery
    TR: transplantation